Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 626 of 6351
-
New hope for stomach and bowel cancers? experimental drug enters human trials
Disease control Recruiting nowThis study will check how well a new medicine, Risvutatug rezetecan, (Ris-Rez, also known as GSK5764227) works, how safe it is and how the body handles it in participants all around the world with advanced inoperable or metastatic gastrointestinal cancer who have previously recei…
Phase 1/2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New hope for blood cancer patients: experimental combo enters final testing phase
Disease control Recruiting nowThe goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The study will also compare how well sonr…
Phase 3 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Jail-Based hep c cure program shows promise in pilot study
Cure Recruiting nowThe goal of this clinical trial is to learn whether a low-barrier treatment program can help people with hepatitis C virus (HCV) who are in jail start and complete treatment more easily. This study focuses on adults at the Rhode Island Department of Corrections who have active HC…
Phase 4 • Sponsor: Lifespan • Aim: Cure
Last updated Jun 27, 2026 09:09 UTC
-
New drug could ease painful muscle condition and cut steroid use
Disease control OngoingThe primary objective of the study is to evaluate the efficacy of olokizumab (OKZ) 64 mg administered subcutaneously every 2 weeks compared with placebo in participants with polymyalgia rheumatica (PMR). The secondary objectives are to evaluate the steroid-sparing effect, inflamm…
Phase 3 • Sponsor: R-Pharm International, LLC • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New pill targets Hard-to-Treat cancers with specific gene mutation
Disease control Recruiting nowPhase 1/2, open-label study of ETX-636 in participants with advanced solid tumors
Phase 1/2 • Sponsor: Ensem Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Supercharged immune cells take on hard-to-treat cancers
Disease control Recruiting nowThe body has different ways of fighting infection and disease. No single way seems perfect for fighting cancers. This research study combines two different ways of fighting cancer: antibodies and T cells. Antibodies are types of proteins that protect the body from infectious dis…
Phase 1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New hope for Hard-to-Treat pancreatic cancer: targeted drug combo shows promise
Disease control OngoingThis study will compare two different regimens for patients with BRCA1/2 or PALB2 mutated metastatic pancreatic cancer after progression on first-line FOLFIRINOX.
Phase 2/3 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Shoulder surgery showdown: which approach wins for seniors?
Disease control By invitation onlyTo compare the one year outcomes between 60 year old patients with a three tendon tear treated as part of their standard of care with either a reverse total shoulder arthroplasty or rotator cuff repair surgery.
Sponsor: Campbell Clinic • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New combo therapy aims to tackle melanoma that resists treatment
Disease control Recruiting nowThere is a lack of strategies for patients who progress after responding to PD-1/l-1 in melanoma. High expression of Nectin4 in skin and melanomas may serve as a new target in advanced melanomas. The combination of enfortumab/vedotin (EV) and pembrolizumab has shown synergistic e…
Phase 2 • Sponsor: Grupo Español Multidisciplinar de Melanoma • Aim: Disease control
Last updated Jun 26, 2026 17:53 UTC
-
Zapping the brain to fight alcoholism: a new hope?
Disease control CompletedThis study looked at whether repetitive transcranial magnetic stimulation (rTMS), a non-invasive brain stimulation treatment, could help adults with alcohol use disorder when added to their usual treatment. Nine adults receiving abstinence-oriented care received 10 sessions of st…
Sponsor: Ting-Gang Chang • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Shorter TB prevention regimens put to the test in major trial
Prevention Recruiting nowOur study rationale is based on: 1. Tuberculosis Preventive Treatment (TPT) is given to healthy people and needs to be safe; 2. Tuberculosis Preventive Treatment (TPT) with shorter regimens are superior with respect to acceptance, completion, and costs; 3. 4 months of Rifampin 1…
Phase 2/3 • Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre • Aim: Prevention
Last updated Jun 27, 2026 12:31 UTC
-
A new approach to vulvar pain: could education and behavior change bring relief?
Symptom relief OngoingThe aim of this SCED-study is to evaluate a multimodal treatment for vulvodynia in young women. The main questions it aims to answer are: Is multimodal treatment effective for provoked vulvodynia in young women? How is multimodal treatment experienced by young women with vulvody…
Sponsor: Region Örebro County • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
New device aims to seal brain aneurysms without surgery
Disease control Recruiting nowThe goal of this clinical trial is to collect additional data to demonstrate if the Contour Neurovascular System (CNS) is a safe and effective treatment of wide-necked, saccular, intracranial aneurysms. Participants will: Undergo treatment with the Contour Neurovascular System …
Sponsor: Cerus Endovascular, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Triple therapy aims to shrink liver tumors before surgery
Disease control Recruiting nowThe goal of this clinical trial is to learn if the neoadjuvant therapy of iIparomlimab and Tuvonralimab plus lenvatinib works to treat hepatocellular carcinoma(HCC) patients with high risk of recurrence. It will also learn about the safety of the combination of iIparomlimab and T…
Phase 2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Could a cell infusion free organ transplant patients from lifelong drugs?
Disease control Recruiting nowThe goal of this clinical trial is to evaluate the safety and feasibility of inducing hematopoietic mixed chimerism to promote immune tolerance and potentially reduce the need for lifelong immunosuppression in pediatric and adult patients undergoing solid organ transplantation (S…
Phase 1 • Sponsor: Francisco Hernández Oliveros • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
One scan to rule them all? new CT aims to replace multiple heart tests
Diagnosis Recruiting nowCardiovascular diseases are the leading cause of death worldwide, responsible for about 30% of all deaths. This substantial burden highlights the need for accurate diagnostic tools that help doctors detect heart disease early and understand it more fully. Recent advances in medic…
Sponsor: Karolinska University Hospital • Aim: Diagnosis
Last updated Sep 04, 2026 00:00 UTC
-
Can a sedative help rebuilt tissue survive after cancer surgery?
Disease control CompletedThis double-blinded randomized controlled trial aims to investigate the effect of intraoperative dexmedetomidine administration on early flap viability and microvascular integrity in cancer patients undergoing elective microvascular reconstructive surgery. The primary outcome is …
Sponsor: Dharmais National Cancer Center Hospital • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New 'Double Punch' CAR T-Cell therapy takes on tough blood cancers
Disease control Recruiting nowThis is a Phase I, prospective, dose-finding study to evaluate the safety, persistence, and clinical activity of GF-CART01 in subjects aged 18-70 with relapsed or refractory (R/R) B-cell hematological malignancies and failure of two-line or more standard chemotherapies or auto-he…
Phase 1 • Sponsor: GenomeFrontier Therapeutics TW Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Sweat away brain fog: exercise may slow Parkinson's cognitive decline
Disease control Recruiting nowCognitive impairment is an acknowledged feature of Parkinson's disease (PD) and often coexists with the classic motor symptoms since their onset. Cognitive symptoms of PD can be differentiated from other neurodegenerative diseases by the affected domains: typically, the executive…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Hope for kids with Friedreich's ataxia: drug already approved for teens now tested in younger children
Disease control Recruiting nowIn this study, researchers will learn more about omaveloxolone, also known as BIIB141 or SKYCLARYS®. Omaveloxolone is already approved for people with Friedreich's Ataxia (FA) who are 16 years of age or older. However, it is not yet available for younger teens and children. The m…
Phase 3 • Sponsor: Biogen • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC